Sign in

    Ahmed Muhammad Rahat

    Research Analyst at Leerink Partners

    Ahmed Muhammad Rahat is an Equity Research Analyst at Leerink Partners specializing in Healthcare Technology, Distribution, and Animal Health sectors. He covers a variety of prominent companies within these sectors, including Owens & Minor and others, delivering detailed research and investment recommendations that inform institutional investors. Since joining Leerink Partners, Ahmed has built a track record of thoughtful sector analysis; however, quantitative performance metrics and industry rankings are not publicly available. His background includes advanced financial accreditation and sector expertise, positioning him as a knowledgeable resource in healthcare market coverage.

    Ahmed Muhammad Rahat's questions to OWENS & MINOR INC/VA/ (OMI) leadership

    Ahmed Muhammad Rahat's questions to OWENS & MINOR INC/VA/ (OMI) leadership • Q1 2025

    Question

    Ahmed Muhammad Rahat, on for Mike Cherny, sought clarification on the $100-$150 million tariff figure, asking if it represents direct impact or potential exposure, what is embedded in guidance, and if price increases aim to preserve margin percentages or gross profit dollars.

    Answer

    Executive Edward Pesicka clarified that the $100-$150 million figure represents the total expected cost increase at the SKU level, which the company plans to fully pass through to customers to cover the higher costs. The expectation is to cover the dollar-for-dollar impact.

    Ask Fintool Equity Research AI

    Ahmed Muhammad Rahat's questions to ICON (ICLR) leadership

    Ahmed Muhammad Rahat's questions to ICON (ICLR) leadership • Q1 2025

    Question

    Ahmed Muhammad Rahat of Bank of America inquired about the elevated level of cancellations, asking if there were any significant outliers or specific concentrations by customer type.

    Answer

    CEO Dr. Steve Cutler responded that there was nothing unusual about the cancellations. He stated they were generally elevated across all customer segments, reflecting the company's overall business portfolio, and that this trend is expected to continue through the year.

    Ask Fintool Equity Research AI

    Ahmed Muhammad Rahat's questions to Certara (CERT) leadership

    Ahmed Muhammad Rahat's questions to Certara (CERT) leadership • Q3 2024

    Question

    Ahmed Muhammad Rahat, on for Michael Cherny, asked about the business setup for 2025, focusing on demand trends from Tier 1 and smaller biotech clients and whether Certara is observing project approval hesitancy similar to its peers.

    Answer

    Executive William Feehery acknowledged that while the sales pipeline is healthy, Certara is experiencing a lengthening of the time to close projects, indicating some customer hesitancy. Executive John Gallagher added that the revised 2024 guidance reflects a challenged end-market environment, with that caution expected to continue into the next year.

    Ask Fintool Equity Research AI